<DOC>
	<DOCNO>NCT01481012</DOCNO>
	<brief_summary>The purpose study obtain data information blood clotting factor activate open heart surgery . In particular , investigator interest blood clot factor activate heart-lung bypass machine leave ventricular assist device ( LVAD ) . Patients two machine increase risk bleed blood clot formation . This machine stimulate intrinsic coagulation pathway , one chemical pathway cause blood clot . The process surgery also stimulate `` extrinsic coagulation pathway , '' chemical pathway cause blood clot . Stimulating coagulation pathway use body 's clotting factor . As result , patient may risk bleed blood clot formation . The investigator would like study blood factor activate surgery , help develop treatment prevent bleed clot formation .</brief_summary>
	<brief_title>The Epidemiology Bleeding Clotting Patients Undergoing Heart Transplantation , Coronary Artery Bypass Graft Surgery , Implantation Left Ventricular Assist Devices</brief_title>
	<detailed_description>This prospective , multi-center , observational study characterize epidemiology bleed clot patient underlie systolic ventricular dysfunction undergo heart transplantation , CABG surgery , implantation leave ventricular assist device . Patients follow 28 day post-implant , post-CABG , post-heart transplant , hospital discharge , whichever come first . There randomization observational study . We enroll 100 patient ( expect distribution approximately 30 per Groups I - III , cap per group , 10 Group IV ) schedule undergo CPB within 24 hour one follow : Group I : Cardiopulmonary Bypass + Heart Transplantation CPB orthotopic heart transplantation ( exclude patient VADs ) Group II : Cardiopulmonary Bypass + Pulsatile LVAD CPB implantation Thoratec HeartMate® I LVAD ( destination therapy bridge transplantation ) Group III : Cardiopulmonary Bypass + Continuous Flow LVAD CPB implantation axial flow centrifugal flow LVAD ( destination therapy bridge transplantation ) ( e.g . HeartMate® II , DeBakey VAD® VentrAssist® LVAS ) Group IV : Cardiopulmonary Bypass + CABG/Valve Surgery CPB CABG valve surgery Heart transplantation perioperative care perform accordance standard care clinical center . Pulsatile LVAD ( e.g . HeartMate® I ) implantation perioperative management perform accordance standard care clinical center , guide HeartMate® I Directions Use . Continuous flow LVAD implantation perioperative management perform accordance standard care clinical center , guide specific VAD manufacturer 's Directions Use . CABG surgery perioperative care perform accordance standard care clinical center . We anticipate enrollment complete six-month period . We hypothesize initial activation intrinsic pathway coagulation attenuate several day patient undergo CPB CABG alone ; however , subject undergo CPB VAD implantation cardiac transplantation , activation pathway biphasic sustain .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Signed informed consent , release medical information , HIPAA form ; 2 . Age great equal 18 year ; 3 . Male , postmenopausal female , female may become pregnant use adequate contraceptive precaution ( defined oral contraceptive , intrauterine device , surgical contraception combination condom spermicide ) , negative pregnancy test ; 4 . Admitted clinical center time enrollment ; 5 . Approved schedule undergo one follow within 24 hour enrollment : Orthotopic heart transplantation CABG and/or valve surgery CPB ; patient must LV ejection fraction ≤35 % Implantation pulsatile LVAD ( e.g.Thoratec HeartMate® I LVAD ) destination therapy bridge transplantation Implantation continuous flow LVAD ( e.g . HeartMate® II , DeBakey VAD® VentrAssist® LVAS ) destination therapy bridge transplantation 1 . History platelet disorder ; 2 . History know , inherit , acquire coagulation disorder study subject ; 3 . Stroke within 30 day prior enrollment ; 4 . Allergy heparin protamine ; 5 . Participation clinical investigational intervention trial , exception investigational VAD trial , time enrollment ; 6 . Received investigational intervention within 30 day enrollment , exception investigational VAD trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Heart transplantation</keyword>
	<keyword>Coronary artery bypass graft ( CABG ) surgery</keyword>
	<keyword>Left ventricular assist device implantation surgery</keyword>
</DOC>